Promising Drug Therapy for Blood Cancer Found After 40 Years

by Iswarya on  August 25, 2018 at 5:58 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

New biological drug for acute leukemia was developed by a research team with a cure rate of 50 percent, reports a new mice study. The findings of the study are published in the journal Cell.
Promising Drug Therapy for Blood Cancer Found After 40 Years
Promising Drug Therapy for Blood Cancer Found After 40 Years

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.

Leukemia produces a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.

To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during "targeted therapy" treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.

However, the new drug developed by Ben-Neriah and his team functions as a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy.

Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.

Additionally promising is the new drug's ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.

"We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice's' leukemia signs disappeared overnight," shared professor Ben-Neriah.

BioTheryX recently bought the rights to this promising drug from HU's technology transfer company Yissum. Together with Ben-Neriah's research team, they are now applying for FDA approval for phase I clinical studies.

Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Drug Toxicity Thalassemia Cancer and Homeopathy Reiki and Pranic Healing Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Drugs Banned in India Hairy Cell Leukemia 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive